Jump to navigation
Supported by an educational grant from Boehringer Ingelheim GmbH.*Medical accuracy confirmed at release date.
This educational site provides a comprehensive curriculum on the management of advanced non–small-cell lung cancer (NSCLC).
This site seeks to provide clinicians with the ability to:
ESMO Clinical Practice Guidelines for Metastatic NSCLC
NCCN Clinical Practice Guidelines for NSCLC (V2.2017)
LUX-Lung 7: Afatinib vs Gefitinib as First-Line Treatment of Patients With EGFR-Mutation–Positive NSCLC
AURA2: Osimertinib for Pretreated EGFR Thr790Met–Positive Advanced NSCLC
IMPRESS: Gefitinib plus Chemotherapy vs Placebo plus Chemotherapy in EGFR-Mutation–Positive NSCLC After Progression on First-Line Gefitinib
LUX-Lung 8: Afatinib vs Erlotinib as Second-Line Treatment of Patients With Advanced Squamous Cell Carcinoma of the Lung
Effect of Dose Adjustment on the Safety and Efficacy of Afatinib for EGFR-Mutation–Positive Lung Adenocarcinoma: Post-Hoc Analyses of the Randomised LUX-Lung 3 and 6 Trials